缬沙坦联合辛伐他汀治疗早期糖尿病肾病临床观察

Clinical study on valsartan and simvastatin in early diabetic nephropathy

目的探讨缬沙坦联合辛伐他汀治疗早期糖尿病肾病的临床疗效及作用机制。方法将80例早期糖尿病肾病患者随机分为对照组40例（缬沙坦80mg，1次／d）、治疗组40例（在对照组治疗基础上加辛伐他汀20mg，每晚一次）。疗程均为12周，比较治疗前后血脂、尿白蛋白排泄率（UAER）、C-反应蛋白（CRP）的变化。结果两组治疗后UAER较治疗前明显减少（均P〈0．01），治疗组减少程度较对照组更明显（P〈0．05）；治疗组治疗后血脂、CRP水平明显下降（P〈0．05）。结论早期糖尿病肾病患者应用缬沙坦联合辛伐他汀治疗能明显降低UAER、CRP，改善血脂，有效延缓肾损害进展。

Objective To observe the effects and the functions of valsartan and simvastatin in early diabetic nephropathy. Methods A total of 80 patients with early diabetic nephropaby were randomly divided into two groups. The patients in control group（ n =40）received valsartan at a dose of 80mg/day,while in treated group（ n =40）on the base of the same＇treatment as control group, added simvastatin 20 mg/everynight. To compare the differences of lipids, urine albumin excretion rate（UAER） and C-reactive protein（CRP） before or after treatments through 12 weeks. Results The UAER of two groups decreased obviously after therapy, especially the treated group（P 〈 0. 01 ） ;the lipids and CRP also decreased evidently in the treated group（P 〈 0. 05 ）. Conclusion The lipids, UAER, CRP of patients in early diabetic nephropathy could be down-regulated, with combined medication of the simvastatin and valsartan, and the injury of renal alleviated.